Nyxoah (NYXH) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Nyxoah's mission is to address the significant unmet needs in Obstructive Sleep Apnea (OSA) treatment by moving beyond the low-compliance standard of CPAP therapy. Its key achievement is the development and regulatory approval of the innovative Genio® neurostimulation system, which features a unique leadless, battery-free design activated by an external patch. The company's strategy is to drive global commercialization of Genio®, expand its clinical evidence base, and pursue label expansions to treat a broader patient population, positioning itself as a leader in the OSA neurostimulation market.

Obstructive Sleep ApneaRespiratory

Technology Platform

The Genio® system is a leadless, battery-free hypoglossal nerve stimulation (HNS) platform for treating Obstructive Sleep Apnea. It uses an implantable neurostimulator powered wirelessly by an external patch to provide bilateral nerve stimulation.

Opportunities

The massive, underserved population of CPAP-intolerant OSA patients represents a multi-billion dollar market.

Nyxoah's differentiated technology and potential label expansion into Complete Concentric Collapse and milder OSA could significantly enlarge its addressable patient base.

Risk Factors

Key risks include commercial execution against an established competitor, securing broad insurance reimbursement, proving long-term safety of its novel design, and the need for continued capital investment before reaching profitability.

Competitive Landscape

Nyxoah's primary competitor is Inspire Medical Systems, which has first-mover advantage. Nyxoah competes on its leadless, battery-free design and bilateral stimulation. The broader competitive set includes CPAP giants (ResMed, Philips) and oral appliance makers.

More companies in Digital Health & Biotech SaaS →More companies in Belgium →